Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice

Ahmet B. Inceoglu, Heather L. Clifton, Jun Yang, Christine Hegedus, Bruce D. Hammock, Saul Schaefer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The use of niacin in the treatment of dyslipidemias is limited by the common side effect of cutaneous vasodilation, commonly termed flushing. Flushing is thought to be due to release of the vasodilatory prostanoids prostaglandin D2 (PGD2) and prostaglandin E2 from arachidonic acid metabolism through the cyclooxygenase pathway. Arachidonic acid is also metabolized by the cytochrome P450 system, which is regulated, in part, by the enzyme soluble epoxide hydrolase (sEH). Methods: These experiments used an established murine model in which ear tissue perfusion was measured by laser Doppler to test the hypothesis that inhibition of sEH would limit niacin-induced flushing. Results: Niacin-induced flushing was reduced from 506 ± 126% to 213 ± 39% in sEH knockout animals. Pharmacologic treatment with 3 structurally distinct sEH inhibitors similarly reduced flushing in a dose-dependent manner, with maximal reduction to 143% ± 15% of baseline flow using a concentration of 1 mg/kg TPAU (1-trifluoromethoxyphenyl-3-(1- acetylpiperidin-4-yl) urea). Systemically administered PGD2 caused ear vasodilation, which was not changed by either pharmacologic sEH inhibition or sEH gene deletion. Conclusions: Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2. sEH inhibition may be a new therapeutic approach to limit flushing in humans.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume60
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Epoxide Hydrolases
Niacin
Vasodilation
Prostaglandin D2
Arachidonic Acid
Ear
Gene Deletion
Prostaglandin-Endoperoxide Synthases
Dyslipidemias
Dinoprostone
Cytochrome P-450 Enzyme System
Prostaglandins
Lasers
Perfusion
Skin
Enzymes

Keywords

  • arachidonic acid
  • dyslipidemia
  • epoxide hydrolase
  • flushing
  • nicotinic acid
  • prostaglandins

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice. / Inceoglu, Ahmet B.; Clifton, Heather L.; Yang, Jun; Hegedus, Christine; Hammock, Bruce D.; Schaefer, Saul.

In: Journal of Cardiovascular Pharmacology, Vol. 60, No. 1, 07.2012, p. 70-75.

Research output: Contribution to journalArticle

Inceoglu, Ahmet B. ; Clifton, Heather L. ; Yang, Jun ; Hegedus, Christine ; Hammock, Bruce D. ; Schaefer, Saul. / Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice. In: Journal of Cardiovascular Pharmacology. 2012 ; Vol. 60, No. 1. pp. 70-75.
@article{24abd7183ac54fadb84580b988de0937,
title = "Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice",
abstract = "Background: The use of niacin in the treatment of dyslipidemias is limited by the common side effect of cutaneous vasodilation, commonly termed flushing. Flushing is thought to be due to release of the vasodilatory prostanoids prostaglandin D2 (PGD2) and prostaglandin E2 from arachidonic acid metabolism through the cyclooxygenase pathway. Arachidonic acid is also metabolized by the cytochrome P450 system, which is regulated, in part, by the enzyme soluble epoxide hydrolase (sEH). Methods: These experiments used an established murine model in which ear tissue perfusion was measured by laser Doppler to test the hypothesis that inhibition of sEH would limit niacin-induced flushing. Results: Niacin-induced flushing was reduced from 506 ± 126{\%} to 213 ± 39{\%} in sEH knockout animals. Pharmacologic treatment with 3 structurally distinct sEH inhibitors similarly reduced flushing in a dose-dependent manner, with maximal reduction to 143{\%} ± 15{\%} of baseline flow using a concentration of 1 mg/kg TPAU (1-trifluoromethoxyphenyl-3-(1- acetylpiperidin-4-yl) urea). Systemically administered PGD2 caused ear vasodilation, which was not changed by either pharmacologic sEH inhibition or sEH gene deletion. Conclusions: Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2. sEH inhibition may be a new therapeutic approach to limit flushing in humans.",
keywords = "arachidonic acid, dyslipidemia, epoxide hydrolase, flushing, nicotinic acid, prostaglandins",
author = "Inceoglu, {Ahmet B.} and Clifton, {Heather L.} and Jun Yang and Christine Hegedus and Hammock, {Bruce D.} and Saul Schaefer",
year = "2012",
month = "7",
doi = "10.1097/FJC.0b013e3182580a5d",
language = "English (US)",
volume = "60",
pages = "70--75",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice

AU - Inceoglu, Ahmet B.

AU - Clifton, Heather L.

AU - Yang, Jun

AU - Hegedus, Christine

AU - Hammock, Bruce D.

AU - Schaefer, Saul

PY - 2012/7

Y1 - 2012/7

N2 - Background: The use of niacin in the treatment of dyslipidemias is limited by the common side effect of cutaneous vasodilation, commonly termed flushing. Flushing is thought to be due to release of the vasodilatory prostanoids prostaglandin D2 (PGD2) and prostaglandin E2 from arachidonic acid metabolism through the cyclooxygenase pathway. Arachidonic acid is also metabolized by the cytochrome P450 system, which is regulated, in part, by the enzyme soluble epoxide hydrolase (sEH). Methods: These experiments used an established murine model in which ear tissue perfusion was measured by laser Doppler to test the hypothesis that inhibition of sEH would limit niacin-induced flushing. Results: Niacin-induced flushing was reduced from 506 ± 126% to 213 ± 39% in sEH knockout animals. Pharmacologic treatment with 3 structurally distinct sEH inhibitors similarly reduced flushing in a dose-dependent manner, with maximal reduction to 143% ± 15% of baseline flow using a concentration of 1 mg/kg TPAU (1-trifluoromethoxyphenyl-3-(1- acetylpiperidin-4-yl) urea). Systemically administered PGD2 caused ear vasodilation, which was not changed by either pharmacologic sEH inhibition or sEH gene deletion. Conclusions: Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2. sEH inhibition may be a new therapeutic approach to limit flushing in humans.

AB - Background: The use of niacin in the treatment of dyslipidemias is limited by the common side effect of cutaneous vasodilation, commonly termed flushing. Flushing is thought to be due to release of the vasodilatory prostanoids prostaglandin D2 (PGD2) and prostaglandin E2 from arachidonic acid metabolism through the cyclooxygenase pathway. Arachidonic acid is also metabolized by the cytochrome P450 system, which is regulated, in part, by the enzyme soluble epoxide hydrolase (sEH). Methods: These experiments used an established murine model in which ear tissue perfusion was measured by laser Doppler to test the hypothesis that inhibition of sEH would limit niacin-induced flushing. Results: Niacin-induced flushing was reduced from 506 ± 126% to 213 ± 39% in sEH knockout animals. Pharmacologic treatment with 3 structurally distinct sEH inhibitors similarly reduced flushing in a dose-dependent manner, with maximal reduction to 143% ± 15% of baseline flow using a concentration of 1 mg/kg TPAU (1-trifluoromethoxyphenyl-3-(1- acetylpiperidin-4-yl) urea). Systemically administered PGD2 caused ear vasodilation, which was not changed by either pharmacologic sEH inhibition or sEH gene deletion. Conclusions: Inhibition of sEH markedly reduces niacin-induced flushing in this model without an apparent effect on the response to PGD2. sEH inhibition may be a new therapeutic approach to limit flushing in humans.

KW - arachidonic acid

KW - dyslipidemia

KW - epoxide hydrolase

KW - flushing

KW - nicotinic acid

KW - prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=84863777749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863777749&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e3182580a5d

DO - 10.1097/FJC.0b013e3182580a5d

M3 - Article

C2 - 22526297

AN - SCOPUS:84863777749

VL - 60

SP - 70

EP - 75

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -